Rankings
▼
Calendar
URGN
UroGen Pharma Ltd.
$917M
Q2 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$3M
Net Income
-$3M
EPS (Diluted)
$-0.28
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$433,000
Balance Sheet
Total Assets
$0
Total Liabilities
$0
Stockholders' Equity
$14M
Cash & Equivalents
-$15M
← FY 2016
All Quarters
Q3 2016 →
URGN Q2 2016 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
